Chinese Journal of Antituberculosis ›› 2018, Vol. 40 ›› Issue (6): 593-598.doi: 10.3969/j.issn.1000-6621.2018.06.009
• Original Articles • Previous Articles Next Articles
Wei SU,Ren-zhong LI,Yun-zhou RUAN,Cai-hong XU,Ming-ting. CHEN()
Received:
2018-03-13
Online:
2018-06-20
Published:
2018-07-24
Wei SU,Ren-zhong LI,Yun-zhou RUAN,Cai-hong XU,Ming-ting. CHEN. Analysis of treatment outcomes and influencing factors of 208 multidrug-resistant pulmonary tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2018, 40(6): 593-598. doi: 10.3969/j.issn.1000-6621.2018.06.009
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2018.06.009
患者类别 | 例数 | 治疗成功 | 失访 | 失败 | 死亡 | ||
---|---|---|---|---|---|---|---|
不良反应 | 其他原因b | 合计 | |||||
初治患者 | 36 | 21(10.1) | 11(5.3) | 0(0.0) | 0(0.0) | 0(0.0) | 4(1.9) |
复治患者 | 172 | 82(39.4) | 36(17.3) | 9(4.3) | 23(11.1) | 32(15.4) | 22(10.6) |
复发 | 75 | 41(19.7) | 16(7.7) | 3(1.4) | 8(3.8) | 11(5.3) | 7(3.4) |
返回 | 5 | 3(1.4) | 0(0.0) | 0(0.0) | 1(0.5) | 1(0.5) | 1(0.5) |
初治失败 | 24 | 3(1.4) | 9(4.3) | 2(1.0) | 4(1.9) | 6(2.9) | 6(2.9) |
复治失败 | 50 | 21(10.1) | 9(4.3) | 3(1.4) | 9(4.3) | 12(5.8) | 8(3.8) |
初治2个月末阳性 | 2 | 1(0.5) | 0(0.0) | 1(0.5) | 0(0.0) | 1(0.5) | 0(0.0) |
其他a | 16 | 13(6.3) | 2(1.0) | 0(0.0) | 1(0.5) | 1(0.5) | 0(0.0) |
合计 | 208 | 103(49.5) | 47(22.6) | 9(4.3) | 23(11.1) | 32(15.4) | 26(12.5) |
影响因素 | 患者 例数 | 治疗成功(103例) | 不良结局(105例) | χ2值 | P值 | ||
---|---|---|---|---|---|---|---|
例数 | 构成比(%) | 例数 | 构成比(%) | ||||
性别 | 0.058 | 0.810 | |||||
男 | 155 | 76 | 49.0 | 79 | 51.0 | ||
女 | 53 | 27 | 50.9 | 26 | 49.1 | ||
年龄(岁) | 25.654 | 0.000 | |||||
<60 | 161 | 95 | 59.0 | 66 | 41.0 | ||
≥60 | 47 | 8 | 17.0 | 39 | 83.0 | ||
职业 | 21.496 | 0.000 | |||||
非农民 | 84 | 58 | 69.0 | 26 | 31.0 | ||
农民 | 124 | 45 | 36.3 | 79 | 63.7 | ||
患者登记分类 | 1.353 | 0.245 | |||||
复治 | 172 | 82 | 47.7 | 90 | 52.3 | ||
初治 | 36 | 21 | 58.3 | 15 | 41.7 | ||
既往使用过二线抗结核药物 | 4.609 | 0.032 | |||||
否 | 124 | 69 | 55.6 | 55 | 44.4 | ||
是 | 84 | 34 | 40.5 | 50 | 59.5 | ||
治疗管理方式 | 0.289 | 0.591 | |||||
住院+门诊治疗 | 73 | 38 | 52.1 | 35 | 47.9 | ||
全疗程门诊治疗 | 135 | 65 | 48.1 | 70 | 51.9 | ||
确诊到开始治疗时间(d) | 0.751 | 0.386 | |||||
<30 | 121 | 63 | 52.1 | 58 | 47.9 | ||
≥30 | 87 | 40 | 46.0 | 47 | 54.0 |
[1] | World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[2] | 王黎霞, 陈明亭, 李仁忠 . 全球基金耐多药结核病控制项目在中国——成就与经验.北京: 人民卫生出版社, 2015. |
[3] | 中华人民共和国卫生部疾病预防控制局, 中华人民共和国卫生部医政司, 中国疾病预防控制中心. 中国结核病防治规划实施工作指南(2008年版).北京: 中国协和医科大学出版社, 2009. |
[4] | World Health Organization . Definitions and reporting framework for tuberculosis-2013 revision(updated December 2014). Geneva: World Health Organization, 2014: 5. |
[5] | 王宇, 王黎霞, 许绍发 . 耐多药肺结核防治管理工作方案.北京: 军事医学科学出版社, 2012. |
[6] |
吴哲渊, 张青, 张祖荣 , 等. 上海市耐多药肺结核防治管理模式效果评价. 中国防痨杂志, 2015,37(11):1118-1125.
doi: 10.3969/j.issn.1000-6621.2015.11.008 URL |
[7] |
吕德良, 谭卫国, 张乐平 , 等. 深圳市耐多药结核病治疗效果及影响因素分析. 中国防痨杂志, 2017,39(2):184-190.
doi: 10.3969/j.issn.1000-6621.2017.02.016 URL |
[8] |
郝晓晖, 姚岚, 孙华 , 等. 老年耐多药肺结核临床特征及转归分析. 中华结核和呼吸杂志, 2014,37(3):188-191.
doi: 10.3760/cma.j.issn.1001-0939.2014.03.009 URL |
[9] | World Health Organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO, 2014. |
[10] |
Falzon D, Gandhi N, Migliori GB , et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J, 2013,42(1):156-168.
doi: 10.1183/09031936.00134712 URL |
[11] |
Xu L, Chen J, Innes AL , et al. Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit. PLoS One, 2017,12(10):e0187076.
doi: 10.1371/journal.pone.0187076 URL pmid: 5663430 |
[12] |
World Health Organization . WHO treatment guidelines for drug-resistant tuberculosis 2016 update. Geneva: WHO, 2016.
URL pmid: 27748093 |
[13] |
苏伟, 阮云洲, 赵津 , 等. 91例耐多药肺结核患者抗结核药物不良反应发生情况分析. 中国防痨杂志, 2014,36(7):458-463.
doi: 10.3969/j.issn.1000-6621.2014.07.010 URL |
[14] | 周美兰, 符志军, 张和武 , 等. 武汉市359例耐多药肺结核患者治疗效果分析. 中国热带医学, 2017,17(3):248-252. |
[15] |
Yang C, Luo T, Shen X , et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis, 2017,17(3):275-284.
doi: 10.1016/S1473-3099(16)30418-2 URL |
[16] |
高谦, 梅建 . 传播才是造成我国结核病高耐药率的主要原因. 中国防痨杂志, 2015,37(11):1091-1096.
doi: 10.3969/j.issn.1000-6621.2015.11.002 URL |
[17] |
Cox H, Hughes J, Daniels J , et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis, 2014,18(4):441-448.
doi: 10.5588/ijtld.13.0742 URL pmid: 24670700 |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||